Nitric oxide attenuates endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 in vascular smooth muscle cells by a cGMP-dependent pathway

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 4, 2007, Pages

  Bouallegue, Ali ^b   Daou, Grace Bou ^b   Srivastava, Ashok K ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Cell signaling; Protein kinase G; Protein synthesis; Vasculoprotection

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 8 BROMO CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; ENDOTHELIN 1; FOCAL ADHESION KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N ACETYL S NITROSOPENICILLAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NITROPRUSSIDE SODIUM; PROTEIN KINASE B;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOLYSIS; DOSE RESPONSE; HYPERTROPHY; IMMUNOBLOTTING; MITOGENICITY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; AORTA, THORACIC; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENZYME INHIBITORS; FOCAL ADHESION KINASE 2; GUANYLATE CYCLASE; HYPERTROPHY; LEUCINE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; OXADIAZOLES; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; RATS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; S-NITROSO-N-ACETYLPENICILLAMINE; SIGNAL TRANSDUCTION;

EID: 35348959414     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01097.2006     Document Type: Article

References (53)

1. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 8: 107-115, 2003.
2. 2-induced PKB phosphorylation in vascular smooth muscle cells. Can J Physiol Pharmacol 84: 777-786, 2006.
3. Barman SA. Effect of nitric oxide on mitogen-activated protein kinases in neonatal pulmonary vascular smooth muscle. Lung 183: 325-335, 2005.
4. i-protein expression and adenylyl cyclase signaling in vascular smooth muscle cells. Free Radic Biol Med 41: 1162-1173, 2006.
5. Battistini B, Chailler P, D'Orleans-Juste P, Briere N, Sirois P. Growth regulatory properties of endothelins. Peptides 14: 385-399, 1993.
6. Bian K, Ke Y, Kamisaki Y, Murad F. Proteomic modification by nitric oxide. J Pharmacol Sci 101: 271-279, 2006.
7. Bogoyevitch MA, Glennon PE, Anderson MB, Clerk A, Lazou A, Marshall CJ, Parker PJ, Sugden PH. Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem 269: 1110-1119, 1994.
8. Bouallegue A, Daou GB, Srivastava AK. Endothelin-1-induced signaling pathways in vascular smooth muscle cells. Curr Vasc Pharmacol 5: 45-52, 2007.
9. Buchwalow IB, Podzuweit T, Bocker W, Samoilova VE, Thomas S, Wellner M, Baba HA, Robenek H, Schnekenburger J, Lerch MM. Vascular smooth muscle and nitric oxide synthase. FASEB J 16: 500-508, 2002.
10. Buchwalow IB, Podzuweit T, Samoilova VE, Wellner M, Haller H, Grote S, Aleth S, Boecker W, Schmitz W, Neumann J. An in situ evidence for autocrine function of NO in the vasculature. Nitric Oxide 10: 203-212, 2004.
11. A receptor reduces neointimal hyperplasia after balloon-induced vascular injury in pigs. J Cardiovasc Pharmacol 30: 33-41, 1997.
12. Cheng TH, Shih NL, Chen SY, Lin JW, Chen YL, Chen CH, Lin H, Cheng CF, Chiu WT, Wang DL, Chen JJ. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol 68: 1183-1192, 2005.
13. Clerk A, Sugden PH. Regulation of phospholipase C and D in rat ventricular myocytes: stimulation by endothelin-1, bradykinin and phenylephrine. J Mol Cell Cardiol 29: 1593-1604, 1997.
14. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol Cell Physiol 267: C1405-C1413, 1994.
15. Daou GB, Srivastava AK. Reactive oxygen species mediate endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells. Free Radic Biol Med 37: 208-215, 2004.
16. Flamant M, Tharaux PL, Placier S, Henrion D, Coffman T, Chatziantoniou C, Dussaule JC. Epidermal growth factor receptor trans-activation mediates the tonic and fibrogenic effects of endothelin in the aortic wall of transgenic mice. FASEB J 17: 327-329, 2003.
17. Foschi M, Chari S, Dunn MJ, Sorokin A. Biphasic activation of p21ras by endothelin-1 sequentially activates the ERK cascade and phosphatidylinositol 3-kinase. EMBO J 16: 6439-6451, 1997.
18. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081-1098, 1998.
19. Heller R, Polack T, Grabner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 144: 49-57, 1999.
20. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ, Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 718: 49-59, 1982.
21. Ignarro LJ, Wood KS, Wolin MS. Regulation of purified soluble guanylate cyclase by porphyrins and metalloporphyrins: a unifying concept. Adv Cyclic Nucleotide Protein Phosphorylation Res 17: 267-274, 1984.
22. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem 272: 10050-10057, 1997.
23. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelinmediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 140: 4659-4668, 1999.
24. 2+ influx and endothelin-1-induced intracellular mitogenic cascades in rabbit internal carotid artery vascular smooth muscle cells. J Cardiovasc Pharmacol 40: 307-314, 2002.
25. - interaction. J Biol Chem 272: 9922-9932, 1997.
26. Kodam H, Fukuda K, Takahashi T, Sano M, Kato T, Tahara S, Hakuno D, Sato T, Manabe T, Konishi F, Ogawa S. Role of EGF receptor and Pyk2 in endothelin-1-induced ERK activation in rat cardiomyocytes. J Mol Cell Cardiol 34: 139-150, 2002.
27. Kodama H, Fukuda K, Takahashi T, Tahara S, Tomita Y, Ieda M, Kimura K, Owada KM, Vuori K, Ogawa S. Selective involvement of p130Cas/Crk/Pyk2/c-Src in endothelin-1-induced JNK activation. Hypertension 41: 1372-1379, 2003.
28. Lahteenmaki T, Sievi E, Vapaatalo H. Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferation in vitro. Br J Pharmacol 125: 402-408, 1998.
29. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 71: 769-777, 1996.
30. Mayer B, Pfeiffer S, Schrammel A, Koesling D, Schmidt K, Brunner F. A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 273: 3264-3270, 1998.
31. Pandey SK, Theberge JF, Bernier M, Srivastava AK. Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate. Biochemistry 38: 14667-14675, 1999.
32. Pollock DM, Keith TL, Highsmith RF. Endothelin receptors and calcium signaling. FASEB J 9: 1196-1204, 1995.
33. Rocic P, Lucchesi PA. Down-regulation by antisense oligonucleotides establishes a role for the proline-rich tyrosine kinase PYK2 in angiotensin II-induced signaling in vascular smooth muscle. J Biol Chem 276: 21902-21906, 2001.
34. Rodriguez A, Fortuno A, Gomez-Ambrosi J, Zalba G, Diez J, Fruhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 148: 324-331, 2007.
35. Sandirasegarane L, Charles R, Bourbon N, Kester M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. Am J Physiol Cell Physiol 279: C225-C235, 2000.
36. Sandirasegarane L, Diamond J. The nitric oxide donors, SNAP and DEA/NO, exert a negative inotropic effect in rat cardiomyocytes which is independent of cyclic GMP elevation. J Mol Cell Cardiol 31: 799-808, 1999.
37. Schlossmann J, Feil R, Hofmann F. Signaling through NO and cGMP-dependent protein kinases. Ann Med 35: 21-27, 2003.
38. Schmidt HH, Walter U. NO at work. Cell 78: 919-925, 1994.
39. Sorokin A, Kozlowski P, Graves L, Philip A. Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. J Biol Chem 276: 21521-21528, 2001.
40. 2 in vascular smooth muscle cells. In: The Hypertrophied Heart, edited by Takeda N, Nagano M, Dhalla NS. Boston: Kluwer Academic, 2000, p. 197-206.
41. Stotz WH, Li D, Johns RA. Exogenous nitric oxide upregulates p21(waf1/cip1) in pulmonary microvascular smooth muscle cells. J Vasc Res 41: 211-219, 2004.
42. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 35: 871-886, 2003.
43. Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB. Cyclic-GMP-dependent protein kinase inhibits the Ras/mitogen-activated protein kinase pathway. Mol Cell Biol 18: 6983-6994, 1998.
44. Takizawa T, Gu M, Chobanian AV, Brecher P. Effect of nitric oxide on DNA replication induced by angiotensin II in rat cardiac fibroblasts. Hypertension 30: 1035-1040, 1997.
45. Wang D, Yu X, Brecher P. Nitric oxide and N-acetylcysteine inhibit the activation of mitogen-activated protein kinases by angiotensin II in rat cardiac fibroblasts. J Biol Chem 273: 33027-33034, 1998.
46. Wang D, Yu X, Brecher P. Nitric oxide inhibits angiotensin II-induced activation of the calcium-sensitive tyrosine kinase proline-rich tyrosine kinase 2 without affecting epidermal growth factor receptor transactivation. J Biol Chem 274: 24342-24348, 1999.
47. Webb DJ. Endothelin: from molecule to man. Br J Clin Pharmacol 44: 9-20, 1997.
48. Wink DA, Cook JA, Kim SY, Vodovotz Y, Pacelli R, Krishna MC, Russo A, Mitchell JB, Jourd'heuil D, Miles AM, Grisham MB. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. Chemical aspects involved in the balance between oxidative and nitrosative stress. J Biol Chem 272: 11147-11151, 1997.
49. Yamauchi J, Miyamoto Y, Kokubu H, Nishii H, Okamoto M, Sugawara Y, Hirasawa A, Tsujimoto G, Itoh H. Endothelin suppresses cell migration via the JNK signaling pathway in a manner dependent upon Src kinase, Rac1, and Cdc42. FEBS Lett 527: 284-288, 2002.
50. Yamboliev IA, Hruby A, Gerthoffer WT. Endothelin-1 activates MAP kinases and c-Jun in pulmonary artery smooth muscle. Pulm Pharmacol Ther 11: 205-208, 1998.
51. Yoshizumi M, Kim S, Kagami S, Hamaguchi A, Tsuchiya K, Houchi H, Iwao H, Kid H, Tamaki T. Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells. Br J Pharmacol 125: 1019-1027, 1998.
52. Yu SM, Hung LM, Lin CC. cGMP-elevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95: 1269-1277, 1997.
53. 2 levels: essential role of cGMP. Am J Physiol Heart Circ Physiol 286: H2103-H2112, 2004.